ASH 2014 | MRD in myeloma and proteasome inhibition in amyloidosis
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses multiple myeloma and amyloidosis. In multiple myeloma, minimum residual disease (MRD) testing is receiving great interest in the evaluation of treatment and as a prognostic marker. In amyloidosis, proteasome inhibition is emerging as an important novel therapy.
Get great new content delivered to your inboxSign up